Renaissance Capital logo

bluebird bio

Priced, Nasdaq: BLUE

Developing gene therapies for severe genetic and orphan diseases.

Industry: Health Care

First Day Return: +58.3%

Developing gene therapies for severe genetic and orphan diseases.
IPO Data
IPO Date 06/18/2013
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $101
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Cambridge, MA, United States
Founded 1992
Employees at IPO 50
Website www.bluebirdbio.com

bluebird bio (BLUE) Performance